Navigation Links
First AXL1717 Clinical Data From Ongoing Phase I/II Study in Cancer Patients has Been Published
Date:9/7/2010

First AXL1717 Clinical Data From Ongoing Phase I/II Study in Cancer Patients has... -- STOCKHOLM, September 7, 2010 /PRNewswire/ --


Advanced Search Search

  
Close
  1. Send a release
  2. Member sign in
  3. Become a member
  4. For journalists
  5. Global sites
PR Newswire: news distribution, targeting and monitoring
  1. Products & Services
  2. Knowledge Center
  3. Browse News Releases
  4. Contact PR Newswire
Publishing & Information Services, Biotechnology, Medical Pharmaceuticals, Pharmaceuticals, New Products & Services, Clinical Trials & Medical Discoveries Click to view news release full screen  

First AXL1717 Clinical Data From Ongoing Phase I/II Study in Cancer Patients has Been Published

 

STOCKHOLM, September 7, 2010 /PRNewswire/ -- Axelar AB today announces that the first submitted medical article on the ongoing phase I/II cancer study with AXL1717 has been published in Acta Oncologica.

The article, including clinical data from a limited group of AXL1717-treated patients, by Drs. Ekman, Bergqvist, Frodin and colleagues, was recently published in Acta Oncologica, Early Online 1-7, 2010. The publication describes four heavily pretreated patients with progressive and advanced squamous non-small cell lung cancer (NSCLC) without any remaining therapeutic options. The patients were treated with AXL1717 for notably long time periods, and in addition to reporting that the drug was well tolerated the authors conclude that during: "more than seven months of AXL1717 treatment as third or fourth line treatment, the reported patients did not develop any additional metastases."

"We are pleased to report the first clinical experience in a peer-reviewed publication. These patients, with squamous NSCLC with tumor progression at baseline, represent a selected subgroup but lack a control group. We are encouraged by the results especially since the data was collected in a phase I setting with the primary objectives to establish the tolerability and pharmacokinetics of AXL1717. Squamous NSCLC is relatively unresponsive to regular cytotoxic chemotherapy but the cells of this cancer have been shown to display a high density of the IGF-1 receptor, the therapeutic target for AXL1717", says Johan Harmenberg, CEO Axelar AB.

TO THE EDITORS

About Axelar

Axelar AB is a Swedish biotech company founded in 2003. The company is developing insulin-like growth factor-1 (IGF-1) receptor inhibitors for treatment of cancer and other diseases. Axelar is part of the Karolinska Development portfolio of companies. http://www.axelar.se

About AXL1717

Axelar's lead compound, AXL1717, provides a novel treatment regimen for a wide range of cancers. AXL1717 is the first targeted oral small-molecule IGF-1 receptor inhibitor with no effect on the insulin receptor. AXL1717 is presently undergoing phase I/II clinical trials and the compound combines a superior preclinical efficacy against numerous tumors with an excellent tolerability profile. Most tumor cells are dependent on the IGF-1 receptor signal pathway and the IGF-1 receptor is therefore regarded as a very promising target for cancer therapy. To date, there are no IGF-1 receptor inhibitor drugs on the market.

About Karolinska Development

Karolinska Development manages one of the largest portfolios of life science companies in Europe. Using a unique business model, the company cost efficiently guides the commercialization of world class life science innovations. Since its inception in 2003, Karolinska Development has built a portfolio of some 40 companies. Among the company's projects, 12 candidate drugs are undergoing clinical trials and it is estimated that a total of more than 20 substances have first-in-class potential. http://www.karolinskadevelopment.com

For further information, please contact: Marek Poszepczynski, VP Business Development, Axelar AB Phone: +46(0)705-58-60-21, e-mail: marek.poszepczynski@axelar.se
'/>"/>

SOURCE Karolinska Development AB and Axelar AB
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. China Cord Blood Corporation to Announce First Quarter Fiscal 2011 Financial Results
2. First Aid Supplier HART Health Acquires Competitor and Continues Expansion
3. Abbott Receives FDA Approval for First Automated Molecular Test for Assessing Hepatitis B Treatment
4. Magic-Seal Packaging Products to Introduce First Vytex® Natural Rubber Latex Napkin Rings
5. Medisafe 1 Technologies Finalises Contract to Develop Prototype of the Worlds First Ever Medicinal Syringe-Locking Device
6. Swiss Breast Cancer Patient Becomes First in World to Receive Treatment Using Gated RapidArc from Varian Medical Systems
7. Elbit Imaging Announces Insightec Treats First Prostate Cancer Patients in Clinical Trials
8. Ascension Orthopedics Implants First PyroCarbon Shoulder Device in United Kingdom
9. BMP Sunstones Hao Wawa (Good Baby) Brand Ranked First Among Chinas Top Three Pediatric Medicine Brands
10. Cyberonics Reports Strong Fiscal 2011 First Quarter Results
11. Ambry Genetics Announces the Addition of Illumina HiSeq 2000 and First 510(K) Approved BeadXpress® to Its Sequencing and Genotyping Capabilities
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/22/2017)... , March 22, 2017  Applied BioMath ( ... to drug research and development, today announced the ... QSP Day 2017 is a day full of ... systems pharmacology (QSP) community. The focus is to ... de-risking and accelerating drug research and development. ...
(Date:3/22/2017)... , March 22, 2017 EarlySense ... today that Newton-Wellesley Hospital, a nationally recognized medical center and ... in patient outcomes following continued implementation of its Early Detection ... of 59% in median nurse response time to alarms. ... According to ...
(Date:3/22/2017)... MARLBOROUGH, Mass. , March 22, 2017 ... that it has completed the acquisition of Cynosure, Inc., ... $66 per share in cash. "We are ... forward to working with Michael Davin and ... in the large, rapidly growing medical aesthetics market," said ...
Breaking Medicine Technology:
(Date:3/23/2017)... ... March 23, 2017 , ... Corra Group ... at competitive pricing. Verisys through its FACIS and other services maintains ... Disciplinary actions. , “We are delighted to be able to offer these various ...
(Date:3/23/2017)... ... March 23, 2017 , ... The ... products, was awarded as winners of American Dreams & Good Housekeeping Seal Initiative, ... jointly by HSN and Good Housekeeping. , Steven Wang, MD ., a ...
(Date:3/23/2017)... (PRWEB) , ... March 23, 2017 , ... The Boulevard ... 10am - 2pm. All events will be located in the Main West Entrance ... a no-cost Child ID event. No appointment is necessary and each child with a ...
(Date:3/23/2017)... ... ... “Beyond and Back”: a true-life testimony of tragedy and the miraculous power of ... a wife, mother and grandmother committed to sharing her many spiritual adventures which affirm ... book presents actual events in the life of her family, which validate her deep ...
(Date:3/23/2017)... ... 2017 , ... Ogden Clinic, the largest multi-specialty group in ... to expand its focus on patient care by providing an advanced check-in and ... Ogden Clinic, we are working to become a different type of provider, one ...
Breaking Medicine News(10 mins):